Karima Boubekeur, PhD, is leaving AstraZeneca to join Tillotts Pharma AG as global head of innovation.
Here's what you should know:
1. Dr. Boubekeur will oversee the company's research and development, as well as business development and licensing.
2. At AstraZeneca, she was vice president of emerging portfolio and search and evaluation. She has more than 30 years of experience in pharmaceuticals, with previous roles at Novartis and Roche.
3. Dr. Boubekeur said, "I am delighted to join Tillotts and the Zeria Group and to be part of a growing team dedicated to improving the quality of life of patients suffering from GI-related diseases. I look forward to working alongside [research and development] leaders, talented employees and partners to build on our core business, drive profitable growth and embrace operational excellence."
4. Tillotts develops products exclusively for the digestive system, currently focusing on inflammatory bowel disease.